Current guidelines recommend albumin as the preferred volume expander in cirrhotic patients with ascites.[5,28] Albumin has been proven to effectively improve hypovolemia, prevent circulatory dysfunction following paracentesis, and enhance outcomes in patients with conditions like spontaneous bacterial peritonitis or hepatorenal syndrome.[29–32] However, the role of albumin in managing EVB in cirrhotic patients remains less clear. This evidence concerns the gene ALB and hepatorenal syndrome.